MPS2 improves on the foundational technology of MPS, a test included in the National Comprehensive Cancer Network® (NCCN®) guidelines related to prostate cancer diagnosis.
The MPS2 algorithm has been developed to optimize accuracy. For biopsy naïve patients, MPS2 is a standalone biomarker test. For patients with a prior negative biopsy, relevant clinical factors are included in the algorithm.
The specificity of the T2:ERG fusion gene, the foundation of MPS2, with a supporting array of 17 other genetic biomarkers that characterize prostate cancer, offers population-specific results with next generation accuracy.
Biopsy Naïve Patients
1/3 of those patients who would receive a negative biopsy result.
Patients With a Prior Negative Biopsy
1/2 of those men who would receive a negative biopsy result.
How MPS2 Is Different
Testing for the Most Specific Prostate Cancer Biomarkers Available
Different populations and each individual have specific genetic histories and necessary clinical paths. That’s why MPS2 is built on a cohort-specific algorithm to optimize diagnostic accuracy and provide clinical flexibility for biopsy naïve patients and patients with a prior negative biopsy.
MPS2 provides the stratified insights you need to continue to guide your patient on the best treatment path.
18 Unique Gene Transcripts
Using a simple post-DRE urine sample, MPS2 analyzes 18 unique gene transcripts shown to predict clinically significant cancer. Among these, the test’s foundation is the novel gene fusion T2:ERG.
T2:ERG is present in most men with prostate cancer and is the most specific prostate cancer biomarker available.
Next-Generation Accuracy and Simplicity
Enhanced diagnostics is as easy as a 30-second urine sample. We do the analysis. You gain greater and personalized insights to guide your patient.
Clear Results. Improved Insights. No Surprises.
We are committed to best-in-class diagnostic testing services to help people live healthy and productive lives. We offer you and your patients simplicity and a stress-free experience.
Clinical Publications and Research
Expert Validation of Precision Molecular Diagnostics
MPS2 and its foundational T2:ERG gene fusion are rooted in award-winning research at the University of Michigan, developed and validated in conjunction with the National Institute of Health’s Early Detection Research Network, and supported by a growing body of peer-reviewed literature.